As Part of an Exploratory Outcome, ABLi Therapeutics Used CND's Syn-One Biomarker Services to Quantify and Visualize a Decrease in Phosphorylated Alpha-Synuclein in Cutaneous Nerves of Patients in a ...
The potency of distributed denial of service attacks has increased steadily but dramatically over the last 14 months. There has been a steady but dramatic increase in the potency of distributed denial ...
Syn-One Biomarker Services employed in ABLi's 201 Trial included the Syn-One Research Test, which uses immunofluorescence technology to detect and visualize synuclein in cutaneous nerves, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback